Another challenge for vaccination therapy is to be able to prime a strong immune response of CTLs through cross‐presentation of the antigens.[75] Ideally, tumor cell antigens should escape from the lysosomal compartment of targeted cells and be loaded onto MHC‐I molecules for presentation to CD8+ T cells instead of being presented to CD4 + T cells after loading onto MHC‐II.[76] For example, Wei et al. This evidence concerns the gene CD8A and neoplasm.